Agios Pharmaceuticals, Inc. (AGIO) is listed on NASDAQ in Pharmaceutical Stocks. It is $33.30, -2.86%, with a $2.0B market cap. RSI is 38.4, near oversold. The latest reported quarter missed estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 38.4 Near Oversold
Market Cap $2.0B
Volume 469.9K
Fundamentals — 10-Q Q2 2026
Revenue $65.5M
Net Income $-199.8M
EPS $-3.38
Gross Margin 93.4%
Operating Margin -336.8%
Net Margin -305.1%
P/E Ratio -9.9x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | Sell | 30,000 | $30.48 | $914,400 | 2026 Aug 4 |
| Gheuens Sarah | Chief Medical Officer | Sell | 4,007 | $37.56 | $150,503 | 2026 Jul 1 |
| Burns James William | Chief Legal Officer | Sell | 3,280 | $34.71 | $113,849 | 2026 Apr 2 |
| Gheuens Sarah | Chief Medical Officer | Sell | 2,940 | $34.71 | $102,047 | 2026 Apr 2 |
| Jones Cecilia | Chief Financial Officer | Sell | 3,141 | $34.71 | $109,024 | 2026 Apr 2 |
| Milanova Tsveta | Chief Commercial Officer | Sell | 3,262 | $34.71 | $113,224 | 2026 Apr 2 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy | Sell | 2,959 | $34.71 | $102,707 | 2026 Apr 2 |
| Goff Brian | Chief Executive Officer | Sell | 19,068 | $34.71 | $661,850 | 2026 Apr 2 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy | Sell | 2,959 | $27.80 | $82,260 | 2026 Mar 5 |
| Washburn Theodore James Jr. | Principal Accounting Officer | Sell | 5,272 | $28.88 | $152,255 | 2026 Mar 3 |
| Goff Brian | Chief Executive Officer | Sell | 18,055 | $28.96 | $522,873 | 2026 Mar 2 |
| Burns James William | Chief Legal Officer | Sell | 5,218 | $28.96 | $151,113 | 2026 Mar 2 |
| Jones Cecilia | Chief Financial Officer | Sell | 5,035 | $28.96 | $145,814 | 2026 Mar 2 |
| Milanova Tsveta | Chief Commercial Officer | Sell | 2,868 | $28.96 | $83,057 | 2026 Mar 2 |
| Scadden David | Director | Sell | 200 | $43.84 | $8,768 | 2025 Nov 12 |
| Gheuens Sarah | Chief Medical Officer | Sell | 2,454 | $43.78 | $107,436 | 2025 Nov 11 |
| Gheuens Sarah | Chief Medical Officer | Sell | 200 | $43.81 | $8,762 | 2025 Oct 30 |
| Gheuens Sarah | Chief Medical Officer | Sell | 3,302 | $43.92 | $145,024 | 2025 Oct 27 |
| Scadden David | Director | Sell | 200 | $41.00 | $8,200 | 2025 Oct 8 |
| Scadden David | Director | Sell | 200 | $40.00 | $8,000 | 2025 Sep 30 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $78.10 | 60.4 | $6.0B |
Take AGIO further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put AGIO in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Agios Pharmaceuticals, Inc. next reports.
Set alerts on AGIO
Get notified when Agios Pharmaceuticals, Inc. hits your price targets or technical conditions are met.
Get Started Free